We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-17.07%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.52B
AUM Growth
-$55.5M
Cap. Flow
+$168M
Cap. Flow %
11.04%
Top 10 Hldgs %
38.58%
Holding
149
New
11
Increased
70
Reduced
43
Closed
11

Top Buys

Rank Stock Value
1
ALGN icon
Align Technology
ALGN
+$41.6M
2
ILMN icon
Illumina
ILMN
+$33.2M
3
TDOC icon
Teladoc Health
TDOC
+$29.8M
4
ISRG icon
Intuitive Surgical
ISRG
+$25.9M
5
ABT icon
Abbott
ABT
+$14.7M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$17.1M
2
KTWO
K2M Group Holdings, Inc
KTWO
+$15.1M
3
EW icon
Edwards Lifesciences
EW
+$14.5M
4
PACB icon
Pacific Biosciences
PACB
+$13.9M
5
LH icon
Labcorp
LH
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 88.15%
2 Industrials 0.99%
3 Technology 0.52%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRC
26
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$18.2M 1.19%
205,008
+19,319
+10% +$1.75M
BAX icon
27
Baxter International
BAX
$11.7B
$16.8M 1.1%
254,543
-8,805
-3% -$592K
ALNY icon
28
Alnylam Pharmaceuticals
ALNY
$35.7B
$16.4M 1.08%
224,385
+4,494
+2% +$346K
FIT
29
DELISTED
Fitbit, Inc. Class A common stock
FIT
$16M 1.05%
3,218,884
+704,984
+28% +$3.64M
WBA
30
DELISTED
Walgreens Boots Alliance
WBA
$15.2M 1%
222,802
-3,216
-1% -$249K
ALXN
31
DELISTED
Alexion Pharmaceuticals
ALXN
$15.2M 1%
155,680
-27,400
-15% -$3.24M
QGEN icon
32
Qiagen
QGEN
$8.49B
$15M 0.99%
410,511
+283,963
+224% +$10.5M
AKCA
33
DELISTED
Akcea Therapeutics Inc
AKCA
$13.8M 0.91%
458,296
+39,800
+10% +$1.12M
MGNX icon
34
MacroGenics
MGNX
$285M
$13.6M 0.89%
1,066,993
+342,691
+47% +$5.75M
CDNA icon
35
CareDx
CDNA
$2.05B
$13.5M 0.89%
536,488
+199,439
+59% +$5.12M
PRAH
36
DELISTED
PRA Health Sciences, Inc.
PRAH
$13.1M 0.86%
142,300
-24,100
-14% -$2.44M
ABMD
37
DELISTED
Abiomed Inc
ABMD
$12.6M 0.83%
38,822
+5,687
+17% +$1.98M
ONC
38
BeOne Medicines Ltd
ONC
$32.4B
$11.7M 0.77%
83,600
+71,980
+619% +$9.55M
LIVN icon
39
LivaNova
LIVN
$4.43B
$11.7M 0.77%
127,510
+11,067
+10% +$1.19M
ALDR
40
DELISTED
Alder Biopharmaceuticals
ALDR
$11.5M 0.76%
1,123,813
+218,559
+24% +$2.8M
SUPN icon
41
Supernus Pharmaceuticals
SUPN
$2.79B
$11.5M 0.75%
345,100
-41,400
-11% -$1.78M
INSM icon
42
Insmed
INSM
$23.5B
$10.6M 0.7%
809,146
+242,845
+43% +$3.87M
CNC icon
43
Centene
CNC
$32.8B
$10.4M 0.68%
180,202
-255,840
-59% -$17.1M
HCM icon
44
HUTCHMED
HCM
$1.86B
$10.2M 0.67%
440,169
+40,140
+10% +$1.25M
GNMK
45
DELISTED
GenMark Diagnostics, Inc
GNMK
$9.72M 0.64%
1,999,540
+660,038
+49% +$3.44M
ZBH icon
46
Zimmer Biomet
ZBH
$17.6B
$9.55M 0.63%
94,867
– –
DXCM icon
47
DexCom
DXCM
$29.6B
$9.32M 0.61%
311,232
+24,644
+9% +$782K
AMGN icon
48
Amgen
AMGN
$198B
$8.75M 0.58%
44,950
+8,000
+22% +$1.56M
NKTR icon
49
Nektar Therapeutics
NKTR
$2.31B
$8.59M 0.56%
17,414
+13,713
+371% +$8.28M
TMO icon
50
Thermo Fisher Scientific
TMO
$198B
$8.21M 0.54%
36,692
+2,221
+6% +$521K
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2018 Portfolio in Review

As of Q4 2018, Bellevue Group held 149 positions worth $1.52B, down 3.5% from $1.58B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Bellevue Group deployed $168M of net new capital in Q4 2018, opening 11 new positions and adding to 70 existing holdings. Its largest new stake was QuidelOrtho: 125,000 shares worth $6.1M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 93% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Centene, an estimated $17.1M trimmed.

  • Bellevue Group's largest Q4 2018 buy was QuidelOrtho: 125,000 shares worth $6.1M.
  • Bellevue Group added most to Align Technology in Q4 2018, an estimated $41.6M increase.
  • Bellevue Group's biggest Q4 2018 reduction was Centene, cutting an estimated $17.1M.
  • Bellevue Group fully exited K2M Group Holdings, Inc in Q4 2018, selling an estimated $15.1M.
  • Bellevue Group's ten largest holdings make up 39% of its $1.52B portfolio in Q4 2018.
  • Bellevue Group opened 11 new positions and closed 11 in Q4 2018.
  • Bellevue Group's portfolio value fell 3.5% quarter-over-quarter to $1.52B.

Based on Bellevue Group's 13F filing for Q4 2018, filed 12 Feb 2019.